Aurora Cannabis Introduces the Company's First Inhalable Resin Cartridges for Patients in the United Kingdom
NASDAQ | TSX: ACB
Canada's Leading Medical Cannabis Company Expands Patient Offering with Innovative Dosage Solution
EDMONTON, AB, April 15, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB), the Canadian-based leading global medical cannabis company, has announced today the availability of medical cannabis concentrates to patients in the United Kingdom (UK). This launch marks the company's meaningful step in offering its proprietary cultivar-specific inhalable cannabis extracts in the UK market. These products are available to patients in Canada and Australia and this launch reinforces Aurora's commitment to expanding patient access to an even greater variety of high-quality, premium medical cannabis globally.
"As a company dedicated to patient care and ensuring we regularly listen to patient feedback – we recognized a real need for a convenient, and discreet consumption option and are excited to introduce a new cannabis format at a promised level of quality," said Trisha Cassidy, Managing Director Aurora UK and Ireland. "Our launch of inhalable cannabis cartridges are another step forward in our mission to provide physicians with a larger variety of high-quality medical cannabis that can meet the growing needs and wishes of patients here in the UK. We look forward to receiving feedback from physicians and patients with this expanded offering."
The two novel cultivar-specific Aurora 1.2g resin cartridges have been developed from two highly sought-after proprietary cultivars: Sourdough (indica) and Electric Honeydew (sativa). The inhalation method of these cartridges offers an ideal solution for fast and controlled delivery of medical cannabis.
Key benefits of cannabis inhalers include:
- Exceptional Flavour Profiles: Connected to popular flower products, these strain-specific cartridges use high-quality terpenes and pure extracts to deliver rich and authentic flavours.
- High Potency: Ensures a powerful, consistent, controllable experience with each dose.
- Safety and Quality: Manufactured in state-of-the-art facilities, adhering to strict TGA-GMP quality control and safety standards. These cartridges contain no additives, representing the pinnacle of cannabis purity.
- User-Friendly Design: Easy to use, making it a convenient, portable and discreet choice for patients.
Aurora's industry-leading portfolio of cannabis products is available nationwide for cannabis retailers to offer. Patients may contact their clinic for further information or consult their doctor.
About Aurora Cannabis Inc.
Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
Contact
For Media: Michelle Lefler | VP, Communications & PR | [email protected]
For Investors: ICR, Inc. | [email protected]
Forward Looking Information:
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's launch of medical cannabis concentrates to patients in the United Kingdom, the availability of those products in that market, and the Company's commitment to expanding patient access to an even greater variety of high-quality, premium cannabis.
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-introduces-the-companys-first-inhalable-resin-cartridges-for-patients-in-the-united-kingdom-302428202.html
SOURCE Aurora Cannabis Inc.